## National MDT for Liver Transplantation of Neuroendocrine Tumour Patients with Liver Metastases

## Patient Pathway for Liver Transplantation for NET LM

- **1.** Referrer assesses [\*nominated NET Specialist] eligibility according to the provided criteria.
- **1A.** If primary and associated disease already resected:

Collate evidence confirming clearance of all macroscopically evident extra-hepatic disease.

Histology report from a NET CoE

Collate operation notes or letter from operating surgeon confirming clearance of all macroscopically evident extra-hepatic disease.

Collate pre-operative imaging/reports.

Collate up to date post-operative imaging/reports.

Collate evidence of disease stability or slow progression [letter, scan reports and imaging]

**Essential:** 

- CT TAP, MRI liver, DOTA PET within 6 months of referral to National MDT
- Histology report from a NET CoE
- **1B.** If primary and associated disease in-situ:

Collate evidence for good likelihood of clearance of primary and associated disease if surgery were to be attempted

Collate evidence of disease stability or slow progression [letter, scan reports and imaging]

CT TAP, MRI liver, DOTA PET within 6 months of referral to National MDT Histology report from a NET CoE

- **2.** Referred to National MDT with above evidence.
- **3.** Discussion at MDT and agreement patient should proceed.
- **4A.** Patient referred for liver transplant assessment to the appropriate LT Centre if extrahepatic disease already resected.
- **4B.** Surgery for primary and associated disease first, then referral for LT assessment.
- **5.** Liver transplant assessment.
- **6A.** Placed on waiting list [National MDT informed].
- **6B.** Turned down and the reason why [National MDT informed]
- **6C.** Delisted without transplant and the reason why [National MDT informed]
- 7. Transplanted [National MDT informed and NHSB&T receives all data]
- **8.** Follow-up by nominated NET specialist and nominated LT Specialist [according to a checklist that shall allow good audit later]
- **9.** Major complication [National MDT informed]
- **10.** Cancer recurrence [National MDT informed]

LT for NET LM patient pathway 22<sup>nd</sup> September 2021 (review date September 2023)